Fig. 1

Experimental design to evaluate (co-)purification kits. Blood from healthy donors, collected in EDTA or citrate tubes, was processed into plasma using a 2-spin protocol. Different plasma volumes were used as input for the different kits: 1 mL and 4 mL for CCF; 2 mL and 4 mL for CAT; 2 mL for MAPss and MAPds; 0.06 mL, 0.2 mL and 0.6 mL for MIRA; 0.06 mL, 0.2 mL and 1 mL for MAX; 0.06 mL and 0.2 mL for MIR. One half of the eluate was DNase treated and reverse transcribed for cfRNA quantification, while the second half remained untouched for cfDNA quantification. Quantification of nucleic acids was performed by digital PCR. *MAP and MAX eluates were concentrated using Vivacon columns and vacuum centrifugation, respectively. Underlined kits (CAT and MAP) are semi-automated procedure systems. CCF: QIAamp ccfDNA/RNA Kit, CAT: iCatcher Circulating cfDNA/cfRNA 4000 kit, MAP: MagNA Pure 24 Total NA Isolation Kit, MIRA: miRNeasy Serum/Plasma Advanced Kit, MAX: Maxwell ccfDNA LV Plasma Kit, MIR: miRNeasy Serum/Plasma Kit